These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 31695975)

  • 1. Cancer of Unknown Primary: A Review on Clinical Guidelines in the Development and Targeted Management of Patients with the Unknown Primary Site.
    Qaseem A; Usman N; Jayaraj JS; Janapala RN; Kashif T
    Cureus; 2019 Sep; 11(9):e5552. PubMed ID: 31695975
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of 3T multiparametric MRI and FDG-PET-CT in the evaluation of occult primary cancer with cervical node metastasis.
    Gődény M; Lengyel Z; Polony G; Nagy ZT; Léránt G; Zámbó O; Remenár É; Tamás L; Kásler M
    Cancer Imaging; 2016 Nov; 16(1):38. PubMed ID: 27814768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Metastatic carcinoma of unknown primary: diagnostic approach using immunohistochemistry.
    Conner JR; Hornick JL
    Adv Anat Pathol; 2015 May; 22(3):149-67. PubMed ID: 25844674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Molecular assignment of tissue of origin in cancer of unknown primary may not predict response to therapy or outcome: a systematic literature review.
    Pentheroudakis G; Greco FA; Pavlidis N
    Cancer Treat Rev; 2009 May; 35(3):221-7. PubMed ID: 19046817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diagnostic and therapeutic management of cancer of an unknown primary.
    Pavlidis N; Briasoulis E; Hainsworth J; Greco FA
    Eur J Cancer; 2003 Sep; 39(14):1990-2005. PubMed ID: 12957453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overview of resistance to systemic therapy in patients with breast cancer.
    Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
    Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
    [TBL] [Abstract][Full Text] [Related]  

  • 7. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk factors for cancers of unknown primary site: Results from the prospective EPIC cohort.
    Kaaks R; Sookthai D; Hemminki K; Krämer A; Boeing H; Wirfält E; Weiderpass E; Overvad K; Tjønneland A; Olsen A; Peeters PH; Bueno-de-Mesquita HB; Panico S; Pala V; Vineis P; Quirós JR; Ardanaz E; Sánchez MJ; Chirlaque MD; Larrañaga N; Brennan P; Trichopoulos D; Trichopoulou A; Lagiou P; Hallmans G; Khaw KT; Key TJ; Riboli E; Canzian F
    Int J Cancer; 2014 Nov; 135(10):2475-81. PubMed ID: 24692151
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Deep Learning-Based Identification of Tissue of Origin for Carcinomas of Unknown Primary Using MicroRNA Expression: Algorithm Development and Validation.
    Raghu A; Raghu A; Wise JF
    JMIR Bioinform Biotechnol; 2024 Jul; 5():e56538. PubMed ID: 39046787
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: Molecular Profiling Assists in the Diagnosis and Treatment of Cancer of Unknown Primary.
    Yu B; Wang Q; Liu X; Hu S; Zhou L; Xu Q; Sun Y; Hu X; Luo Z; Zhang X
    Front Oncol; 2022; 12():723140. PubMed ID: 35433426
    [TBL] [Abstract][Full Text] [Related]  

  • 11.
    Thapa P; Kalshetty A; Basu S
    World J Nucl Med; 2018; 17(4):219-222. PubMed ID: 30505217
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular gene expression profiling to predict the tissue of origin and direct site-specific therapy in patients with carcinoma of unknown primary site: a prospective trial of the Sarah Cannon research institute.
    Hainsworth JD; Rubin MS; Spigel DR; Boccia RV; Raby S; Quinn R; Greco FA
    J Clin Oncol; 2013 Jan; 31(2):217-23. PubMed ID: 23032625
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of molecular profiling in the diagnosis and management of metastatic undifferentiated cancer of unknown primary
    Dermawan JK; Rubin BP
    Semin Diagn Pathol; 2021 Nov; 38(6):193-198. PubMed ID: 33309276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cancer of Unknown Primary origin in the genomic era: Elucidating the dark box of cancer.
    Economopoulou P; Mountzios G; Pavlidis N; Pentheroudakis G
    Cancer Treat Rev; 2015 Jul; 41(7):598-604. PubMed ID: 26033502
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Diagnosis and management of metastatic neoplasms with unknown primary.
    Bochtler T; Löffler H; Krämer A
    Semin Diagn Pathol; 2018 May; 35(3):199-206. PubMed ID: 29203116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A comparison of DNA sequencing and gene expression profiling to assist tissue of origin diagnosis in cancer of unknown primary.
    Posner A; Prall OW; Sivakumaran T; Etemadamoghadam D; Thio N; Pattison A; Balachander S; Fisher K; Webb S; Wood C; DeFazio A; Wilcken N; Gao B; Karapetis CS; Singh M; Collins IM; Richardson G; Steer C; Warren M; Karanth N; Wright G; Williams S; George J; Hicks RJ; Boussioutas A; Gill AJ; Solomon BJ; Xu H; Fellowes A; Fox SB; Schofield P; Bowtell D; Mileshkin L; Tothill RW
    J Pathol; 2023 Jan; 259(1):81-92. PubMed ID: 36287571
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal-Cell Carcinoma (mRCC) Histologic and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature.
    Overby A; Duval L; Ladekarl M; Laursen BE; Donskov F
    Clin Genitourin Cancer; 2019 Feb; 17(1):e32-e37. PubMed ID: 30268423
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cancer of Unknown Primary in Adolescents and Young Adults: Clinicopathological Features, Prognostic Factors and Survival Outcomes.
    Raghav K; Mhadgut H; McQuade JL; Lei X; Ross A; Matamoros A; Wang H; Overman MJ; Varadhachary GR
    PLoS One; 2016; 11(5):e0154985. PubMed ID: 27171493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gene expression profiling in patients with carcinoma of unknown primary site: from translational research to standard of care.
    Hainsworth JD; Greco FA
    Virchows Arch; 2014 Apr; 464(4):393-402. PubMed ID: 24487792
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prophylactic Oophorectomy: Reducing the U.S. Death Rate from Epithelial Ovarian Cancer. A Continuing Debate.
    Piver MS
    Oncologist; 1996; 1(5):326-330. PubMed ID: 10388011
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.